CCG-224406

CAS No. 1870843-22-3

CCG-224406( CCG 224406 | CCG224406 )

Catalog No. M12895 CAS No. 1870843-22-3

A highly selective and potent GRK2 (G protein-coupled receptor kinase 2) inhibitor with IC50 of 130 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CCG-224406
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly selective and potent GRK2 (G protein-coupled receptor kinase 2) inhibitor with IC50 of 130 nM.
  • Description
    A highly selective and potent GRK2 (G protein-coupled receptor kinase 2) inhibitor with IC50 of 130 nM; displays >700-fold selectivity over other GRK subfamilies, and no detectable inhibition of ROCK1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CCG 224406 | CCG224406
  • Pathway
    Others
  • Target
    GRK (GPCRK)
  • Recptor
    GRK (GPCRK)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1870843-22-3
  • Formula Weight
    558.57
  • Molecular Formula
    C29H27FN6O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1NC(C2=CC=C(F)C(C(NCC3=C(OC)C=CC=C3OC)=O)=C2)C(C(NC4=CC5=C(C=C4)NN=C5)=O)=C(C)N1
  • Chemical Name
    4-(3-((2,6-dimethoxybenzyl)carbamoyl)-4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Waldschmidt HV, et al. J Med Chem. 2016 Apr 28;59(8):3793-807.
molnova catalog
related products
  • GRK6-IN-1

    GRK6-IN-1 (compound 18) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 of 120 nM, and has potential for study in multiple myeloma.

  • GRK6-IN-2

    GRK6-IN-2 is a potent G protein-coupled receptor kinase 6 (GRK6) inhibitor with potential antitumor activity.GRK6-IN-2 has been studied in multiple myeloma.

  • Takeda103A

    Takeda103A is the GRK2-dependent bovine tubulin oxidation effective inhibitor.